Angiomax: Tortured path to a lot of competition

It has been a long road for Angiomax bivalirudin, a direct thrombin inhibitor derived from the leech compound hirudin. Biogen Inc. stopped development of the compound, then called Hirulog, in 1994 after a Phase III trial in angioplasty failed to show the compound's superiority to heparin. In March 1997, BGEN sold the compound

Read the full 539 word article

How to gain access

Continue reading with a
two-week free trial.